(COLL) Collegium Pharmaceutical - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 1.105m USD | Total Return: 15.2% in 12m

Opioids, ADHD Medication, Laxatives, Pain Management
Total Rating 47
Safety 68
Buy Signal -0.63
Drug Manufacturers - Specialty & Generic
Industry Rotation: -4.2
Market Cap: 1.11B
Avg Turnover: 13.3M
Risk 3d forecast
Volatility34.8%
VaR 5th Pctl5.94%
VaR vs Median3.71%
Reward TTM
Sharpe Ratio0.45
Rel. Str. IBD13.3
Rel. Str. Peer Group13.6
Character TTM
Beta0.740
Beta Downside0.729
Hurst Exponent0.535
Drawdowns 3y
Max DD41.07%
CAGR/Max DD0.39
CAGR/Mean DD1.06
EPS (Earnings per Share) EPS (Earnings per Share) of COLL over the last years for every Quarter: "2021-03": 0.96, "2021-06": 0.81, "2021-09": 0.78, "2021-12": -0.51, "2022-03": 0.91, "2022-06": 1.21, "2022-09": 1.1, "2022-12": -0.21, "2023-03": 1.32, "2023-06": 1.26, "2023-09": 1.34, "2023-12": 1.58, "2024-03": 1.45, "2024-06": 1.62, "2024-09": 0.29, "2024-12": 1.77, "2025-03": 1.49, "2025-06": 1.68, "2025-09": 0.84, "2025-12": 2.04, "2026-03": 1.76,
EPS CAGR: 15.93%
EPS Trend: 71.6%
Last SUE: 1.33
Qual. Beats: 1
Revenue Revenue of COLL over the last years for every Quarter: 2021-03: 87.721, 2021-06: 82.942, 2021-09: 78.843, 2021-12: 27.362, 2022-03: 83.751, 2022-06: 123.549, 2022-09: 127.013, 2022-12: 129.62, 2023-03: 144.767, 2023-06: 135.546, 2023-09: 136.709, 2023-12: 149.745, 2024-03: 144.923, 2024-06: 145.276, 2024-09: 159.301, 2024-12: 181.949, 2025-03: 177.757, 2025-06: 188, 2025-09: 209.361, 2025-12: 205.449, 2026-03: 193.52,
Rev. CAGR: 16.87%
Rev. Trend: 97.8%
Last SUE: 1.30
Qual. Beats: 1

Warnings

Share dilution 22.0% YoY

Fakeout Below Avwap Earnings

Tailwinds

No distinct edge detected

Description: COLL Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on the development and commercialization of pain management and central nervous system (CNS) therapies. Its portfolio includes extended-release and abuse-deterrent formulations of oxycodone and tapentadol (Xtampza ER and Nucynta), as well as buprenorphine buccal films (Belbuca) and treatments for ADHD (Jornay PM).

The company operates within the specialty pharmaceuticals sector, where business models often prioritize the acquisition or development of proprietary delivery technologies to extend the lifecycle of established molecules. This strategy aims to mitigate the risks associated with opioid misuse while addressing the high regulatory barriers inherent in the pain management market.

For a detailed analysis of the companys valuation and growth metrics, investors may find it useful to explore the data on ValueRay.

Headquartered in Stoughton, Massachusetts, the firm also markets Symproic for the treatment of opioid-induced constipation. By focusing on differentiated delivery systems, Collegium seeks to capture market share in a highly regulated landscape governed by stringent FDA oversight and evolving prescribing guidelines.

Headlines to Watch Out For
  • Market share expansion of Belbuca and Xtampza ER drives top-line revenue growth
  • Managed care contract wins improve commercial access and net product pricing
  • Integration of acquired assets like Jornay PM enhances therapeutic portfolio diversification
  • Potential generic competition for key pain products threatens long-term cash flows
  • Regulatory shifts in opioid prescribing patterns impact total addressable market volume
Piotroski VR-10 (Strict) 6.5
Net Income: 74.9m TTM > 0 and > 6% of Revenue
FCF/TA: 0.20 > 0.02 and ΔFCF/TA 7.92 > 1.0
NWC/Revenue: 39.02% < 20% (prev 6.15%; Δ 32.87% < -1%)
CFO/TA 0.20 > 3% & CFO 331.0m > Net Income 74.9m
Net Debt (391.5m) to EBITDA (607.3m): 0.64 < 3
Current Ratio: 1.71 > 1.5 & < 3
Outstanding Shares: last quarter (40.1m) vs 12m ago 22.00% < -2%
Gross Margin: 60.68% > 18% (prev 0.58%; Δ 6.01k% > 0.5%)
Asset Turnover: 48.51% > 50% (prev 40.72%; Δ 7.79% > 0%)
Interest Coverage Ratio: 1.65 > 6 (EBITDA TTM 607.3m / Interest Expense TTM 162.9m)
Altman Z'' 2.09
A: 0.19 (Total Current Assets 745.7m - Total Current Liabilities 435.0m) / Total Assets 1.65b
B: -0.05 (Retained Earnings -86.6m / Total Assets 1.65b)
C: 0.16 (EBIT TTM 268.5m / Avg Total Assets 1.64b)
D: -0.06 (Book Value of Equity -86.8m / Total Liabilities 1.34b)
Altman-Z'' = 2.09 = BBB
Beneish M -3.34
DSRI: 0.83 (Receivables 228.8m/228.7m, Revenue 796.3m/664.3m)
GMI: 0.95 (GM 60.68% / 57.69%)
AQI: 0.81 (AQ_t 0.54 / AQ_t-1 0.66)
SGI: 1.20 (Revenue 796.3m / 664.3m)
TATA: -0.16 (NI 74.9m - CFO 331.0m) / TA 1.65b)
Beneish M = -3.34 (Cap -4..+1) = AA
What is the price of COLL shares?

As of May 30, 2026, the stock is trading at USD 33.61 with a total of 489,996 shares traded.
Over the past week, the price has changed by -2.35%, over one month by -0.44%, over three months by -19.34% and over the past year by +15.18%.

Is COLL a buy, sell or hold?

Collegium Pharmaceutical has received a consensus analysts rating of 4.20. Therefore, it is recommended to buy COLL.

  • StrongBuy: 2
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the COLL price?
Analysts Target Price 54.3 61.6%
Collegium Pharmaceutical (COLL) - Fundamental Data Overview as of 26 May 2026
Market Cap USD = 1.11b (1.11b USD * 1.0 USD.USD)
P/E Trailing = 16.5388
P/E Forward = 4.5809
P/S = 1.3876
P/B = 3.5338
Revenue TTM = 796.3m USD
EBIT TTM = 268.5m USD
EBITDA TTM = 607.3m USD
Long Term Debt = 770.2m USD (from longTermDebt, last quarter)
Short Term Debt = 34.1m USD (from shortTermDebt, last quarter)
Debt = 813.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 5.24m
Net Debt = 391.5m USD (calculated: Debt 813.3m - CCE 421.8m)
Enterprise Value = 1.50b USD (1.11b + Debt 813.3m - CCE 421.8m)
Interest Coverage Ratio = 1.65 (Ebit TTM 268.5m / Interest Expense TTM 162.9m)
EV/FCF = 4.54x (Enterprise Value 1.50b / FCF TTM 329.8m)
FCF Yield = 22.04% (FCF TTM 329.8m / Enterprise Value 1.50b)
FCF Margin = 41.42% (FCF TTM 329.8m / Revenue TTM 796.3m)
Net Margin = 9.41% (Net Income TTM 74.9m / Revenue TTM 796.3m)
Gross Margin = 60.68% ((Revenue TTM 796.3m - Cost of Revenue TTM 313.2m) / Revenue TTM)
Gross Margin QoQ = 60.59% (prev 62.49%)
Tobins Q-Ratio = 0.91 (Enterprise Value 1.50b / Total Assets 1.65b)
Interest Expense / Debt = 20.03% (Interest Expense 162.9m / Debt 813.3m)
Taxrate = 22.65% (4.24m / 18.7m)
NOPAT = 207.7m (EBIT 268.5m * (1 - 22.65%))
Current Ratio = 1.71 (Total Current Assets 745.7m / Total Current Liabilities 435.0m)
Debt / Equity = 2.60 (Debt 813.3m / totalStockholderEquity, last quarter 312.4m)
Debt / EBITDA = 0.64 (Net Debt 391.5m / EBITDA 607.3m)
Debt / FCF = 1.19 (Net Debt 391.5m / FCF TTM 329.8m)
Total Stockholder Equity = 280.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.57% (Net Income 74.9m / Total Assets 1.65b)
RoE = 20.43% (Net Income TTM 74.9m / Total Stockholder Equity 366.9m)
RoCE = 23.61% (EBIT 268.5m / Capital Employed (Equity 366.9m + L.T.Debt 770.2m))
RoIC = 18.53% (NOPAT 207.7m / Invested Capital 1.12b)
WACC = 11.52% (E(1.11b)/V(1.92b) * Re(8.59%) + D(813.3m)/V(1.92b) * Rd(20.03%) * (1-Tc(0.23)))
Discount Rate = 8.59% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -55.56 | Cagr: -1.85%
[DCF] Terminal Value 68.44% ; FCFF base≈276.5m ; Y1≈317.0m ; Y5≈466.5m
[DCF] Fair Price = 126.5 (EV 4.49b - Net Debt 391.5m = Equity 4.10b / Shares 32.4m; r=11.52% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 71.55 | EPS CAGR: 15.93% | SUE: 1.33 | # QB: 1
Revenue Correlation: 97.81 | Revenue CAGR: 16.87% | SUE: 1.30 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.72 | Chg30d=-1.53% | Revisions=-11% | Analysts=5
EPS next Quarter (2026-09-30): EPS=2.08 | Chg30d=+7.51% | Revisions=+56% | Analysts=5
EPS current Year (2026-12-31): EPS=7.72 | Chg30d=+4.58% | Revisions=+33% | GrowthEPS=+4.0% | GrowthRev=+12.0%
EPS next Year (2027-12-31): EPS=7.61 | Chg30d=+26.11% | Revisions=+56% | GrowthEPS=-1.4% | GrowthRev=+1.3%
[Analyst] Revisions Ratio: +56%